Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications i…
Medical - Diagnostics & Research
US, San Diego [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 5.45 | 1.75 | 1.66 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -1.83 | 23.84 | 24.28 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.19 | 36.06 | 36.13 | |
| Cash | 5.79 | 7.01 | 6.63 | |
| Capex | 29.41 | -0.23 | -0.32 | |
| Free Cash Flow | -76.16 | 0.26 | 1.08 | |
| Revenue | -4.10 | 6.77 | 7.06 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 3.04 | 0.62 | 0.60 | |
| Operating Margin | -7.93 | -0.05 | -0.05 | |
| ROA | 27.90 | -0.01 | -0.02 | |
| ROE | 28.27 | -0.02 | -0.03 | |
| ROIC | -14.37 | < 0.005 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ILMN is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ILMN is permitted for members.
6
Leverage & Liquidity